MarketLens

Is Gilead's GH31 Acquisition a Game-Changer for Its Oncology Pipeline

7 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Gilead's Oncology and Inflammation Wave: Why the Market is Underpricing Diversification

2 months ago

Has Pfizer's Seagen Acquisition Reshaped the Oncology Landscape

4 months ago

Is Herbalife's Bioniq Acquisition a Game-Changer for its Personalized Nutrition Strategy

5 months ago

Is Brookfield's $1.2 Billion World Freight Acquisition a Game Changer

3 months ago

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead's dividend and HIV revenue remain strong, but its enterprise relies on one blockbuster drug facing patent expiry in about a decade, raising long-term sustainability concerns.

GILD

Stock News•3 weeks ago

EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC

Gilead's Trodelvy received EU approval for first-line metastatic TNBC use with Keytruda, expanding its label and strengthening the company's oncology growth opportunity.

GILD

Stock News•2 months ago

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics fell >30% since prior coverage, but remains a Buy with BB-8520 showing 65% ORR and 100% DCR in KRAS G12C NSCLC. Mature data readouts due 2H26 could be key catalysts.

BBOT

Breaking News

Top Headlines

View More →

Stock News•44 minutes ago

Shell (SHEL) Ascends While Market Falls: Some Facts to Note

Stock News•1 hour ago

Chipotle Mexican Grill (CMG) Registers a Bigger Fall Than the Market: Important Facts to Note

Stock News•1 hour ago

Amazon (AMZN) Dips More Than Broader Market: What You Should Know

Stock News•1 hour ago

Meta plans to launch camera-free smart glasses for fall, The Information reports

Stock News•1 hour ago

Is Gilead's GH31 Acquisition a Game-Changer for Its Oncology Pipeline

Exclusive Content for Pro Members

Related Articles

Gilead's Oncology and Inflammation Wave: Why the Market is Underpricing Diversification

Has Pfizer's Seagen Acquisition Reshaped the Oncology Landscape

Is Herbalife's Bioniq Acquisition a Game-Changer for its Personalized Nutrition Strategy

Is Brookfield's $1.2 Billion World Freight Acquisition a Game Changer

Category

You may also like

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Shell (SHEL) Ascends While Market Falls: Some Facts to Note

Chipotle Mexican Grill (CMG) Registers a Bigger Fall Than the Market: Important Facts to Note

Amazon (AMZN) Dips More Than Broader Market: What You Should Know

Meta plans to launch camera-free smart glasses for fall, The Information reports

Microsoft announces quarterly dividend increase